Telix Pharmaceuticals Ltd. (TLX) saw its stock surge 10% in after-hours trading on Tuesday, following the announcement that a research center in Miami has begun recruiting and dosing patients for the company's Phase 3 clinical trial of TLX591, an investigational treatment for advanced prostate cancer.
The ProstACT Global Phase 3 trial is evaluating TLX591, a radioantibody-drug conjugate (rADC) that targets prostate-specific membrane antigen (PSMA), in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer (mCRPC). The trial aims to assess the safety and efficacy of TLX591 as a first-line or second-line treatment option for this patient population.
The Biogenix Molecular Research Center in Miami has successfully administered the first two doses of TLX591 to a local patient and continues to recruit eligible participants for the trial. According to the center's director, Dr. Frankis Almaguel, there is a significant unmet need for effective combination therapies in mCRPC, and TLX591 has shown promising results in earlier-stage trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.